louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05451511: COVID-19 Resource Offers Among Rent and Utility Assistance Applicants in St. Louis
Official title: Rapid Acceleration of Diagnostics Underserved Populations Supplement Rent Relief and COVID-19 in St. Louis: COVID-19 Resource Offers Among Rent and Utility Assistance Applicants in St. Louis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Behavior and Behavior Mechanisms
Communication
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
First posted: 2022-07-11
Enrollment: 531
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this study is to evaluate health messaging strategies that help individuals with a high degree of housing-related needs engage in COVID-19 vaccination and testing behaviors. Findings from this research can help other communities determine how best to integrate social needs and COVID-19 prevention services. Participants' contact information will be shared with us by 211 with the participants' previously given consent. The study team will send via text message a link to a survey that includes a screen where they will provide informed consent. Those who provide consent will be randomly assigned to receive one of two surveys. The order of the offers is what varies across the surveys. Participants will be asked, along with other survey items, if they have been vaccinated against COVID-19. If they have not, they will be asked if they are interested in receiving help to receive a vaccine. Participants will also be asked if they are interested in receiving an at-home COVID self-test. If they say yes to assistance with vaccination, a vaccine navigator will call and assist them. If they say yes to receiving a COVID test, the study team will ship them a test that has been procured from the City of St. Louis Mayor's office. One month later participants will be sent a follow-up survey that asks about their experiences either with testing or with vaccination if applicable.


Eligibility criteria: Inclusion Criteria:

* Applicants for rent and utility assistance in St. Louis City or County
* English language proficiency
* Be willing to be contacted via text message or email
* Resident of St. Louis City or County

Exclusion Criteria:

* N/A

Primary outcomes:
measure: Proportion Vaccinated
timeFrame: Baseline
measure: Sequential Request Strategy Effectiveness
timeFrame: Baseline
measure: Testing and Vaccination Offer Acceptance
timeFrame: Baseline
Secondary outcomes:
measure: Testing and Vaccination Behaviors
timeFrame: 1 month follow-up
measure: Rent Relief
timeFrame: Baseline
Other outcomes:
Locations:
city: Saint Louis
country: United States
facility: Washington University in St. Louis
state: Missouri
Study officials:
References:
Clinical trial NCT03562611: Postoperative Pain and Discomfort After Orbital Decompression
Official title: Flurbiprofen Axetil and Nalbuphine for Postoperative Pain and Discomfort After Orbital Decompression
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Surgery
Anesthesia
Pain
Keywords: postoperative pain
general anesthesia
postoperative discomfort
Lead sponsor: Sun Yat-sen University
Sponsor class: OTHER
First posted: 2018-06-19
Enrollment: 63
Sex: ALL
Minimum age (years): 16
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the postoperative pain and discomfort using flurbiprofen axetil or nalbuphine administration after orbital decompression under general anesthesia.

Detailed description: To investigate postoperative analgesia achieved with intraoperative administration of intravenous nalbuphine and flurbiprofen axetil in patients undergoing orbital decompression

Eligibility criteria: Inclusion Criteria:

* 16-75 years old
* diagnosed as thyroid eye disease
* bone removal orbital decompression under general anesthesia
* American Society of Anesthesiologists (ASA) physical status of I-II

Exclusion Criteria:

* body mass index (BMI) \<18.5 or \>35
* any uncontrolled clinical problems

Primary outcomes:
measure: Pain after orbital decompression
timeFrame: 24 hour after recovery
Secondary outcomes:
measure: Discomfort after orbital decompression
timeFrame: 24 hour after recovery
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Sun Yat-sen University
state: Guangdong
Study officials:
affiliation: Sun Yat-sen University
name: Huijing Ye
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05318911: Antithrombotic Activities of a Novel Yogurt Drink
Official title: Antithrombotic Activities of a Novel Yogurt Drink: a Dietary Intervention Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiovascular Diseases
Lead sponsor: University of Limerick
Sponsor class: OTHER
First posted: 2022-04-08
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: This study aims to evaluate antithrombotic activities of novel yoghurt drink in healthy adult volunteers

Detailed description: This randomized controlled, double-blinded crossover study aims to investigate the antithrombotic activities of a novel yoghurt drink in healthy adult volunteers. It is anticipated that the novel drink containing beneficial polar lipids will reduce platelet aggregation in participants and consequently decrease the onset of cardiovascular disease.

In Phase I, the subjects will provide blood samples after overnight fasting and then take either a yoghurt drink (YD) or placebo (that does not contain polar lipids) daily for 4 weeks. Following this period, they will again provide blood samples. Then, after a 2-week washout period in which the subjects do not take any yoghurt or placebo drink , Phase II of the clinical trial will commence. This is the crossover phase in which subjects who took YD will now be given a placebo drink, and vice versa, over 4 weeks. A total of 80 blood samples will be collected for analysis.

Eligibility criteria: Inclusion Criteria:

* Healthy adults

Exclusion Criteria:

* Volunteers need to be off medication and off any dietary supplements.
* Subjects must not have any blood clotting disorders or dyslipidaemia.
* Dairy intake needs to be within a normal range of 1-2 portions a week.
* Unwilling to follow the study requirements.

Primary outcomes:
measure: Platelet aggregation of PRP samples in the presence of PAF
timeFrame: Participants' platelet activity will be assessed for up to roughly 6 months through study completion
measure: Screening of plasma levels of cholesterol ( PL, LDL, HDL, VLDL).
timeFrame: The outcomes of this testing will be assessed for up to roughly 6 months through study completion.
measure: Screening plasma levels of inflammatory markers.
timeFrame: The outcomes of this testing will be assessed for up to roughly 6 months through study completion.
measure: Screening plasma levels of triglycerides.
timeFrame: The outcomes of this testing will be assessed for up to roughly 6 months through study completion.
Secondary outcomes:
Other outcomes:
Locations:
city: Limerick
country: Ireland
facility: University of Limerick
Study officials:
References:
citation: Tsoupras A, Zabetakis I, Lordan R. Platelet aggregometry assay for evaluating the effects of platelet agonists and antiplatelet compounds on platelet function in vitro. MethodsX. 2018 Dec 26;6:63-70. doi: 10.1016/j.mex.2018.12.012. eCollection 2019.
Clinical trial NCT00212511: Evaluation of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through an IPF Registry
Official title: Prospective Evaluation of Patients With Idiopathic Pulmonary Fibrosis Through an IPF Registry
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Idiopathic Pulmonary Fibrosis
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2005-09-21
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with interstitial lung disease.

Brief summary: The purpose of this study is to create a database of demographics and samples in idiopathic pulmonary fibrosis.


Eligibility criteria: Inclusion Criteria

1. Male or Female greater or equal to age 18.
2. Referral by physician with the diagnosis of IPF, or interstitial lung disease (IPF considered likely).

Exclusion Criteria

(a) Unwilling or unable to give written informed consent.

Primary outcomes:
measure: Determine cellular and molecular determinants of IPF
timeFrame: Long-Term
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: NYU School of Medicine
state: New York
Study officials:
affiliation: NYU School of Medicine, Division of Pulmonary and Critical Care Medicine
name: Rany Condos, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01396811: Topical Antifungal Treatment for Tinea Pedis
Official title: A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Pedis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Tinea Pedis
Keywords: Tinea Pedis
Antifungal
Lead sponsor: Medicis Global Service Corporation
Sponsor class: INDUSTRY
First posted: 2011-07-19
Enrollment: 322
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if a topical antifungal cream is safe and effective for the treatment of tinea pedis.


Eligibility criteria: Inclusion Criteria:

* Moderate erythema, moderate scaling, and mild pruritus

Exclusion Criteria:

* Pregnancy and allergies

Primary outcomes:
measure: Proportion of patients achieving complete clearance
timeFrame: Day 42
Secondary outcomes:
measure: Proportion of patients achieving effective treatment
timeFrame: Day 42
Other outcomes:
Locations:
city: Miami
country: United States
state: Florida
city: Miramar
country: United States
state: Florida
city: Augusta
country: United States
state: Georgia
city: Evansville
country: United States
state: Indiana
city: Warren
country: United States
state: Michigan
city: Hackensack
country: United States
state: New Jersey
city: High Point
country: United States
state: North Carolina
city: Cinncinnati
country: United States
state: Ohio
city: Philadelphia
country: United States
state: Pennsylvania
city: Nashville
country: United States
state: Tennessee
city: Belize City
country: Belize
Study officials:
affiliation: Medicis Pharmaceutical
name: Ron Staugaard
role: STUDY_DIRECTOR
References:
Clinical trial NCT06938711: A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer
Official title: A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With Estrogen Receptor-Positive, Progesterone Receptor-Positive, HER2-negative Advanced or Metastatic Breast Cancer
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE1
PHASE2
Conditions: Breast Cancer
Lead sponsor: Context Therapeutics Inc.
Sponsor class: INDUSTRY
First posted: 2025-04-22
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a rollover study for patients enrolled in the discontinued ELONA clinical trial (ONA-XR-103) with the primary objective to characterize the safety of elacestrant in combination with onapristone either alone or in combination.


Eligibility criteria: Inclusion Criteria:

* Patient is currently enrolled in the ELONA clinical study (ONA-XR-103) and receiving onapristone or elacestrant, either alone or in combination.
* Patient is currently benefiting from the treatment in the ELONA clinical study, as determined by the investigator.
* Patient currently has no evidence of progressive disease, as determined by the investigator.

Exclusion Criteria:

* Pregnant or nursing (lactating) women.
* Female patients of childbearing potential (e.g., are menstruating) who do not agree to abstinence or, if sexually active, do not agree to the use of highly effective contraception, throughout the study and for up to 30 days after stopping study treatment.

Primary outcomes:
measure: Characterize the safety of elacestrant in combination with onapristone.
timeFrame: 7 months
Secondary outcomes:
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Sarah Cannon Research Institute
state: Tennessee
Study officials:
References:
Clinical trial NCT01780311: Catheter Ablation Versus Antiarrhythmic Drugs for Outflow Tract Ventricular ARrhythmias
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Ventricular Tachycardia
Ventricular Premature Complexes
Lead sponsor: Ospedale San Donato
Sponsor class: OTHER
First posted: 2013-01-31
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no

Brief summary: A randomized, parallel, open study comparing catheter ablation versus antiarrhythmic drugs for outflow tract ventricular arrhythmias


Eligibility criteria: Inclusion Criteria:

1. presence of ventricular ectopic beats (VEB) with left-bundle-branch block morphology or right-bundle-branch block morphology and positive concordance throughout the chest leads, inferior axis and at least one of the following:

1. \>2000 isolated VEB/24h
2. symptomatic monomorphic ventricular tachycardia
3. left ventricular disfunction supposed to be due to tachycardia-induced cardiomyopathy

Exclusion Criteria:

1. known structural heart disease
2. pregnancy
3. life expectancy \< 1 year

Primary outcomes:
measure: SF-36 score
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Arezzo
country: Italy
facility: Cardiovascular Department, Ospedale S.Donato
state: AR
Study officials:
References:
Clinical trial NCT05005611: Probiotics Regulates Skin Care in Children
Official title: Probiotics Regulates Skin Care in Children : A Randomized, Double-blind Clinical Trial With Placebo
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Skin Care
Probiotics
Children
Lead sponsor: Chang Gung Memorial Hospital
Sponsor class: OTHER
Collaborators: name: Glac Biotech Co., Ltd
First posted: 2021-08-13
Enrollment: 148
Sex: ALL
Minimum age (years): 1
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Skin Care in children.
Primary purpose: SUPPORTIVE_CARE

Brief summary: Probiotics, a component that is generally referred to as a living microorganism or a microorganism present in a host. Most studies have shown that probiotics can regulate immune function in the body. Many studies have attempted to understand whether the use of probiotics can prevent allergic diseases or not.


Eligibility criteria: Inclusion Criteria:

* Estimated by PI.

Exclusion Criteria:

* Be allergic to medicine
* Take medicine like immune inhibition, or steroid injection in two weeks
* Participate in another clinical research or immune therapy in one month
* Have severe disease
* Inappropriate for this trial judged by PI

Primary outcomes:
measure: Skin severity scoring
timeFrame: 3 months
Secondary outcomes:
measure: Blood analysis
timeFrame: 3 months
measure: NGS in gastrointestinal tract
timeFrame: 3 months
measure: Life quality
timeFrame: 3 months
Other outcomes:
Locations:
city: Kaohsiung City
country: Taiwan
facility: Kaohsiung Chang Gung Memorial Hospital
Study officials:
References:
Clinical trial NCT06790511: Clinical Performance of Bioactive Highly Filled Injectable Flowable Composite for Direct Posterior Occlusal Conservative Restorations Using FDI Criteria: Two Year Randomized Clinical Trial
Official title: Clinical Performance of Bioactive Highly Filled Injectable Flowable Composite for Direct Posterior Occlusal Conservative Restorations Using FDI Criteria: Two Year Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: EARLY_PHASE1
Conditions: Dental Caries
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2025-01-24
Enrollment: 50
Sex: ALL
Minimum age (years): 16
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate Clinical Performance of bioactive highly filled injectable flowable composite for direct posterior occlusal conservative restorations using FDI Criteria


Eligibility criteria: Inclusion Criteria:The inclusion criteria: patient age range from 16-45 years, with a premolar indicated for extraction, patients required at least a couple of Class I restorations. The patient should have good general health.

-

Exclusion Criteria:Where the exclusion criteria will be: poor oral hygiene, sever or chronic periodontal disease or bruxism, severe tooth sensitivity, non-vital or fracture or cracked teeth, defective restorations or bleaching procedures during the last 6 months, pregnancy, and/or lactation, and allergy to the main components of the products to be used in the study.

-

Primary outcomes:
measure: Recurrence of caries
timeFrame: 24 Months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01025011: Non-invasive Measurement of Hemoglobin in Retinal Arteries
Official title: Non- Invasive Measurement of the Absolute Hemoglobin Value in the Retinal Arteries of Anemic and Healthy Subjects Using a New Approach
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Healthy Subjects
Anemia
Keywords: retinal hemoglobin concentration
non-invasive hemoglobin measurement
Lead sponsor: Triemli Hospital
Sponsor class: OTHER
First posted: 2009-12-03
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Sampling method: NON_PROBABILITY_SAMPLE
Study population: healthy subjects from the eye clinic of Triemli Hospital anemic and pregnant patients from the gynecology department, Triemli Hospital

Brief summary: The purpose of this study is to test a new non-invasive tool to measure hemoglobin in retinal arteries.

Detailed description: To our knowledge no tool exists that allows for direct collection of hemoglobin data in the eye. In many eye diseases (especially diabetic and hypertensive retinopathy as well as in retinal vessel occlusions) retinal circulation is modified. Knowing hemoglobin concentration on the site of the pathology will give us further information about the pathogenesis of this diseases and may provide a new possibility in therapy.

The purpose of this study is to test a new non-invasive tool to measure hemoglobin in retinal arteries. Healthy volunteers from the eye clinic and pregnant otherwise healthy patients of the gynecological department of the Triemli Hospital, Zurich, as well as anemic gynecological patients that show up for a check-up are included.

Hemoglobin will be quantified by a blood draw of a cubital vein. Using a Fundus Camera (Nidek AFC-230) pictures of the fundus will be taken from each study patient. Afterwards the study investigator selects a retinal artery of interest which will be used for measuring the hemoglobin concentration. Intensity of the green channel of the camera chip is determined with the aid of the law of Lambert-Beer.

Absolute Hemoglobin concentration is calculated in relation to the vessel volume.

Eligibility criteria: Inclusion Criteria:

* healthy volunteers
* pregnant patients from the Triemli Hospital that came for a routine check up
* anemic patients of the same dept with various gynecological tumors

Exclusion Criteria:

* any known retinal eye disease
* poor fundus picture quality due to fixtion problems or too small pupil or media intransparency
* not willing to participate in a study

Primary outcomes:
measure: Correlation of hemoglobin concentration measured in a cubital vein and in a non invasive way using hemoglobinometry in the retinal veins
timeFrame: 2.5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Zürich
country: Switzerland
facility: Stadtpital Zürich, Triemli Hospital
Study officials:
affiliation: Triemli Hospital
name: Yves Robert, Prof MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00004311: Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Acanthosis Nigricans
Polycystic Ovary Syndrome
Keywords: acanthosis nigricans
dermatologic disorders
endocrine disorders
polycystic ovarian syndrome
rare disease
Lead sponsor: Office of Rare Diseases (ORD)
Sponsor class: NIH
Collaborators: name: Baylor College of Medicine
First posted: 1999-10-19
Sex: FEMALE
Minimum age (years): 0
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: OBJECTIVES: I. Evaluate insulin resistance in thin and obese hyperandrogenic women with polycystic ovarian disease or hyperandrogenism insulin resistance acanthosis nigricans syndrome and in thin and obese controls, using an estimation of tissue sensitivity to insulin.

II. Evaluate the effect of androgen suppression with leuprolide acetate and spironolactone on insulin secretion and resistance.

Detailed description: PROTOCOL OUTLINE: Participants are treated with subcutaneous leuprolide acetate followed by oral spironolactone. Each treatment is administered daily for 6 weeks, with a 6-week washout between drugs.

Patients and controls are alternately assigned to begin treatment with leuprolide acetate or spironolactone.

Eligibility criteria: PROTOCOL ENTRY CRITERIA:

--Disease Characteristics-- Polycystic ovarian disease Oligomenorrhea or amenorrhea Hirsutism Hyperandrogenism Hyperandrogenism insulin resistance acanthosis nigricans syndrome Hyperandrogenism Oligomenorrhea or amenorrhea Insulin resistance Acanthosis nigricans Hematocrit at least 30% Women with normal menstrual cycles not using oral contraception entered as controls

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Baylor College of Medicine
name: Karen E. Elkind-Hirsch
role: STUDY_CHAIR
References: